Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
Taiwan · Delayed Price · Currency is TWD 138.00
+7.50 (5.75%)
May 29, 2026, 1:30 PM CST
TPEX:3218 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,171 | 4,204 | 4,228 | 4,082 | 3,494 | 2,632 | |
Revenue Growth (YoY) | -2.56% | -0.57% | 3.58% | 16.83% | 32.76% | 28.18% |
Cost of Revenue | 1,729 | 1,721 | 1,695 | 1,634 | 1,354 | 995.36 |
Gross Profit | 2,441 | 2,483 | 2,533 | 2,448 | 2,140 | 1,636 |
Selling, General & Admin | 1,120 | 1,105 | 1,133 | 1,132 | 1,051 | 867.59 |
Operating Expenses | 1,120 | 1,102 | 1,135 | 1,137 | 1,059 | 867.91 |
Operating Income | 1,321 | 1,380 | 1,398 | 1,312 | 1,081 | 768.54 |
Interest Expense | -25.74 | -24.84 | -20.94 | -15.83 | -13.56 | -13.16 |
Interest & Investment Income | 65.15 | 67.53 | 39.58 | 19.16 | 6.93 | 4.07 |
Currency Exchange Gain (Loss) | -5.51 | -5.51 | 7.9 | -0.06 | 9.8 | -2.57 |
Other Non Operating Income (Expenses) | -28.07 | 5.72 | 2.16 | 3.59 | 9.6 | 6.03 |
EBT Excluding Unusual Items | 1,327 | 1,423 | 1,427 | 1,319 | 1,094 | 762.91 |
Gain (Loss) on Sale of Investments | -61.89 | -61.89 | -100.22 | - | - | - |
Gain (Loss) on Sale of Assets | -0.62 | -0.62 | -8.92 | -1.37 | -2.22 | -0.22 |
Asset Writedown | -16.17 | -16.17 | - | - | - | - |
Other Unusual Items | 1.12 | 1.12 | 0.57 | 1.23 | 0.41 | 0.42 |
Pretax Income | 1,250 | 1,346 | 1,318 | 1,319 | 1,092 | 763.11 |
Income Tax Expense | 277.35 | 290.98 | 267.82 | 254.56 | 223.98 | 152.45 |
Earnings From Continuing Operations | 972.36 | 1,055 | 1,050 | 1,064 | 868.11 | 610.66 |
Minority Interest in Earnings | -11.6 | -11.96 | 14.5 | -18.93 | -17.58 | -15.23 |
Net Income | 960.76 | 1,043 | 1,065 | 1,045 | 850.53 | 595.43 |
Net Income to Common | 960.76 | 1,043 | 1,065 | 1,045 | 850.53 | 595.43 |
Net Income Growth | -14.48% | -2.07% | 1.88% | 22.88% | 42.84% | 23.22% |
Shares Outstanding (Basic) | 85 | 85 | 85 | 85 | 85 | 85 |
Shares Outstanding (Diluted) | 86 | 85 | 85 | 85 | 85 | 85 |
Shares Change (YoY) | 0.95% | 0.10% | 0.08% | 0.04% | 0.03% | -0.03% |
EPS (Basic) | 11.24 | 12.31 | 12.57 | 12.34 | 10.04 | 7.03 |
EPS (Diluted) | 11.20 | 12.26 | 12.53 | 12.31 | 10.02 | 7.02 |
EPS Growth | -15.27% | -2.15% | 1.79% | 22.85% | 42.76% | 23.22% |
Free Cash Flow | 1,083 | 1,104 | 1,237 | 1,081 | 778.47 | 587.33 |
Free Cash Flow Per Share | 12.63 | 12.98 | 14.56 | 12.73 | 9.17 | 6.92 |
Dividend Per Share | - | 7.750 | 7.500 | 7.000 | 5.660 | 4.492 |
Dividend Growth | - | 3.33% | 7.14% | 23.67% | 26.00% | 19.05% |
Gross Margin | 58.54% | 59.05% | 59.91% | 59.98% | 61.24% | 62.18% |
Operating Margin | 31.68% | 32.83% | 33.06% | 32.14% | 30.94% | 29.20% |
Profit Margin | 23.04% | 24.80% | 25.18% | 25.60% | 24.34% | 22.62% |
Free Cash Flow Margin | 25.98% | 26.25% | 29.27% | 26.48% | 22.28% | 22.32% |
EBITDA | 1,681 | 1,728 | 1,739 | 1,592 | 1,295 | 942.85 |
EBITDA Margin | 40.31% | 41.11% | 41.12% | 38.99% | 37.06% | 35.83% |
D&A For EBITDA | 359.63 | 347.89 | 340.67 | 279.84 | 213.63 | 174.32 |
EBIT | 1,321 | 1,380 | 1,398 | 1,312 | 1,081 | 768.54 |
EBIT Margin | 31.68% | 32.83% | 33.06% | 32.14% | 30.94% | 29.20% |
Effective Tax Rate | 22.19% | 21.63% | 20.32% | 19.30% | 20.51% | 19.98% |